These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25155368)

  • 1. Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.
    Jen MH; Kurth H; Iheanacho I; Dinet J; Gabriel S; Wasiak R; Jost WH
    J Med Econ; 2014 Nov; 17(11):803-9. PubMed ID: 25155368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale.
    Espay AJ; Trosch R; Suarez G; Johnson J; Marchese D; Comella C
    Parkinsonism Relat Disord; 2018 Jul; 52():94-97. PubMed ID: 29530726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
    Dressler D; Kupsch A; Seitzinger A; Paus S
    Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
    Tarsy D
    Mov Disord; 1997 Jan; 12(1):100-2. PubMed ID: 8990061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
    Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
    Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia.
    Skogseid IM; Malt UF; Røislien J; Kerty E
    Eur J Neurol; 2007 Oct; 14(10):1129-37. PubMed ID: 17708754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
    Dashtipour K; Mari Z; Jankovic J; Adler CH; Schwartz M; Brin MF
    J Neurol Sci; 2019 Oct; 405():116413. PubMed ID: 31494402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inter-rater reliability while using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in patients with cervical dystonia].
    Kaji R; Osawa M; Yanagisawa N
    Brain Nerve; 2009 Jan; 61(1):65-71. PubMed ID: 19177808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia.
    Barbosa PM; Rodrigues GR; de Oliveira DS; de Souza CP; Tumas V
    Clin Neuropharmacol; 2015; 38(6):221-6. PubMed ID: 26536017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
    J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study.
    Mordin M; Masaquel C; Abbott C; Copley-Merriman C
    BMJ Open; 2014 Oct; 4(10):e005150. PubMed ID: 25324317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
    Samotus O; Lee J; Jog M
    J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital.
    Queiroz MR; Chien HF; Barbosa ER
    Arq Neuropsiquiatr; 2011 Dec; 69(6):900-4. PubMed ID: 22297876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport
    Simonetta-Moreau M; Picaut P; Volteau M; Poewe W
    Eur J Neurol; 2019 Jun; 26(6):943-e65. PubMed ID: 30168896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
    Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.